Institute Of Biomedical Stock Probability Of Bankruptcy
| MRES Stock | USD 0.01 0.0006 7.50% |
Institute |
Institute of Biomedical Company probability of financial unrest Analysis
Institute's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Institute Probability Of Bankruptcy | Less than 10% |
Most of Institute's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Institute of Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Institute probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Institute odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Institute of Biomedical financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Institute of Biomedical has a Probability Of Bankruptcy of 10.0%. This is 76.9% lower than that of the Healthcare sector and 81.77% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 74.89% higher than that of the company.
Institute Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Institute's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Institute could also be used in its relative valuation, which is a method of valuing Institute by comparing valuation metrics of similar companies.Institute is currently under evaluation in probability of bankruptcy category among its peers.
Institute Fundamentals
| Current Valuation | 198.84 K | |||
| Shares Outstanding | 66.28 M | |||
| Price To Book | 0.69 X | |||
| Revenue | 1.41 M | |||
| Net Income | 564.67 K | |||
| Cash Flow From Operations | 2.06 M | |||
| Beta | 1.71 | |||
| Market Capitalization | 639.61 K | |||
| Total Asset | 5.28 M | |||
| Retained Earnings | (55.58 M) | |||
| Current Asset | 2.56 M | |||
| Current Liabilities | 3.8 M | |||
| Z Score | -14.0 | |||
| Net Asset | 5.28 M |
About Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Institute of Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Institute of Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.